SMN1-Negative Adult Weakness: What the New LRP12 Finding Means
Direct answer: A negative SMN1 test does not exclude every inherited form of spinal muscular atrophy. A Japanese research team found expanded CGG repeats in LRP12 in six of eight families with carefully selected, previously unresolved adult-onset non-5q SMA. This is an important diagnostic clue, but it is an observational genetic case series—not an approved treatment, a clinical trial, or proof that LRP12 explains most adults with weakness.
Why a “negative genetic test” may not close the case
Adults with slowly progressive weakness may move among several diagnostic labels: motor neuron disease, muscular dystrophy, hereditary neuropathy, or a non-5q form of SMA. The overlap is especially difficult when weakness is proximal, sensation is preserved, and electromyography suggests chronic lower motor neuron loss.
Many patients have already had an SMA test, a gene panel, or whole-exome sequencing. Yet every test has boundaries. Whole-exome sequencing is designed mainly to read protein-coding regions and is relatively good at small sequence variants. It may not reliably detect or size GC-rich repeat expansions in noncoding regions. “No variant found” therefore means no reportable explanation was found with that method; it does not mean every genetic mechanism was excluded.
What the Japanese study actually reported
Researchers from the University of Tokyo Hospital and Japan’s National Center of Neurology and Psychiatry studied eight consecutive families that met predefined criteria for adult-onset non-5q SMA and remained genetically unresolved after comprehensive testing, including whole-exome sequencing. They screened LRP12 with repeat-primed PCR and confirmed and sized expansions with Oxford Nanopore long-read sequencing.
Six probands carried expansions of 58 to 92 CGG repeats. Five of the six positive families showed a pattern consistent with autosomal-dominant inheritance. The reported phenotype was adult onset, slow progression, predominantly proximal pure lower motor neuron weakness, generally preserved sensory and bulbar function, and no upper motor neuron signs.
The researchers also found expansions in two of 496 people in an ALS comparison group and two of 1,000 controls. Because the main cohort was small, highly selected, and referred after previous testing failed, the “six of eight” result cannot be treated as a prevalence estimate for the general SMA or weakness population.
What a second opinion may reassess
- Does the clinical pattern fit? Age at onset, distribution and pace of weakness, reflexes, sensory findings, swallowing, breathing, and upper motor neuron signs help distinguish 5q-SMA, non-5q SMA, ALS, Kennedy disease, neuropathy, and myopathy.
- What did the prior genetic test actually cover? A report review should identify whether copy-number changes, repeat expansions, mitochondrial variants, and noncoding regions were assessed—not simply note that “exome testing was negative.”
- Does the electrophysiology support a motor neuron pattern? Original EMG and nerve-conduction findings may reveal chronic denervation, sensory involvement, a myopathic pattern, or a focal explanation.
- Is targeted repeat testing justified? Repeat-primed PCR or long-read sequencing should be considered in context, rather than offered as a universal test for fatigue or weakness.
- How should a positive result be interpreted? Repeat length, laboratory validation, segregation within the family, clinical fit, and genetic counseling all matter. One laboratory value should not be used for self-diagnosis.
Who may benefit from a structured review?
A specialist second opinion may be useful for an adult with slowly progressive proximal weakness or atrophy, lower motor neuron findings on EMG, a negative SMN1 result, and no diagnosis after a well-documented panel or exome test. A family history of similar symptoms increases the reason to review the testing strategy, but an apparently negative family history does not settle the question.
This pathway is not designed for every person with fatigue, pain, or intermittent weakness. Sudden weakness, rapidly worsening breathing, marked swallowing difficulty, frequent falls, or a new one-sided deficit requires prompt local evaluation. An overseas record review is not an emergency service.
Treatment boundaries matter
The study improves diagnostic thinking; it does not establish an LRP12-directed therapy. Treatments developed for 5q-SMA target the SMN pathway and should not be assumed to work for an LRP12-associated non-5q disorder simply because both conditions use the term “SMA.” A clearer diagnosis may still be valuable for counseling, surveillance, supportive care planning, and research eligibility, but it does not guarantee a new treatment option.
Records that make a second opinion more useful
- A dated symptom and functional timeline
- A three-generation family history
- Neurological examination notes and original EMG/nerve-conduction conclusions
- SMN1, androgen receptor repeat testing when relevant, and previous panel or exome reports
- The laboratory’s coverage statement and information about retained raw data, if available
- Creatine kinase, thyroid, metabolic, and immune testing
- Relevant brain or spine imaging and respiratory or swallowing assessments
- Three to five specific questions for the reviewing specialist
Practical next step
Ask a neuromuscular or neurogenetics team to review the phenotype, family structure, electrophysiology, and technical limits of previous testing together. The decision may be to reinterpret existing data, order a different test, or conclude that another diagnostic pathway is more appropriate. A Japan Expert Second Opinion can help structure that review, but the written opinion should be discussed with the clinician responsible for local care.
A second opinion may confirm the present pathway, recommend more testing, or refine genetic counseling. It does not guarantee a changed diagnosis or treatment, and it does not automatically require travel to Japan.
Frequently asked questions
Does an SMN1-negative result rule out SMA?
No. It makes classic 5q-SMA less likely, but genetically diverse non-5q SMA syndromes and phenocopies remain possible.
Can whole-exome sequencing miss LRP12 repeat expansions?
Yes. GC-rich noncoding repeat expansions may not be reliably detected or sized by conventional short-read exome methods. The test design must be reviewed.
Does an LRP12 expansion establish the diagnosis by itself?
No. Laboratory quality, repeat size, family segregation, population context, and clinical fit must be considered together.
Is there an approved LRP12-targeted treatment?
No approved targeted treatment was established in the sources reviewed. This publication concerns diagnosis, not treatment efficacy.
Must a patient travel to Japan?
No. Many recommendations concern test selection, data reinterpretation, and genetic counseling that can first be discussed with a local team.
Risk notice
This article is for medical education and decision support. It does not provide a diagnosis, prescription, test-eligibility decision, or outcome guarantee. Do not post medical records, imaging, or identity documents in public comments.
Primary sources
- University of Tokyo Hospital research release, September 28, 2026.
- National Center of Neurology and Psychiatry research release, September 28, 2026.
- LRP12 CGG Repeat Expansions in Patients With Adult-Onset Non-5q Spinal Muscular Atrophy, Neurology Genetics, September 23, 2026. DOI: 10.1212/NXG.0000000000200440.
Evidence checked: September 29, 2026.
Japan Expert Second Opinion: A structured written review may help identify the next diagnostic question to take back to the local neurology team. Medical information should be transferred only through a private, secure process.